Hughes, B., Grob, J.-J. ., Bowyer, S., Day, F. ., Ladwa, R., Stein, B. ., Muñoz-Couselo, E., Basset-Seguin, N., Guminski, A. ., Mortier, L. ., Hauschild, A. ., Migden, M. ., Schmults, C. ., Yoo, S.-Y., Booth, J. ., Seebach, F. ., Lowy, I. ., Fury, M., & Rischin, D. . (2023). Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. SKIN The Journal of Cutaneous Medicine, 7(2), s175. https://doi.org/10.25251/skin.7.supp.175